Coenzyme Q10 for Gulf War Illness

This study is looking at whether a high-quality Coenzyme Q10 supplement, called PharmaNord Bio-Quinone Active CoQ10 Gold 100mg, can help improve symptoms, daily function, and quality of life for veterans with Gulf War illness (also known as Persian Gulf Syndrome). You might be able to join if you are a veteran aged 50 or older, meet specific criteria for Gulf War illness, and don't have certain health conditions. The study will compare different doses of the CoQ10 supplement to a placebo (an inactive substance). Researchers will measure how many of your symptoms improve over 3.5 months to see if the CoQ10 is beneficial. The study plans to enroll 192 participants, but its current status is unclear.

Study design: This interventional study plans to enroll 192 participants and compares different doses of PharmaNord Bio-Quinone Active CoQ10 Gold 100mg against a placebo.
What's involved: You would take softgels three times a day and travel to a local Quest facility for blood draws. You would also participate in ZoomPro visits and complete surveys online.
Compensation: Not stated in the trial record.
Follow-up: The primary outcome is measured at 3.5 months.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

Coenzyme Q10 for Gulf War Illness: A Replication Study

Recruiting

PHASE3Ages 50+InterventionalTreatment

University of California, San Diego

~192 participants

Updated 2026-05-01 on ClinicalTrials.gov

What's tested:PharmaNord Bio-Quinone Active CoQ10 Gold 100mgPharmaNord Placebo

At a glance

Recruiting sites

1 of 1 listed site is recruiting right now

RecruitingSuspended, closed, or not yet open

What they're measuring

Number of symptoms (out of 20 on the UCSD Symptom Score Survey) showing more favorable change (trend or effect) on active treatment vs. on placebo.

Measured over 3.5 months

Conditions

Gulf War Syndrome

Persian Gulf Syndrome

Mitochondrial Disorder, Respiratory Chain

NCT06515184

Where you'd take part

This study runs at 1 site. They're the same protocol — you choose where, and that choice sets who your contact draft is addressed to.

UC San Diego
La Jolla, Californiastudy coordinator listed
Recruiting

Sites open and close at different times, so the status above is per site — it can differ from the study's overall status.

Study leadership

Beatrice A Golomb, MD, PhD · PRINCIPAL_INVESTIGATOR · University of California, San Diego

Who to contact

Janis B Ritchie, BSN

[email protected]

858-558-4950

Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Want this trial checked against your situation?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime

Eligibility criteria

Inclusion

Does not have a disqualifying condition.

Able to travel to a local Quest facility for study blood draws.

Adequate internet access to allow ZoomPro visit participation and remote survey completion.

Health prior to the Gulf War rated as "very good" or "excellent" (to exclude persons who may have had other health conditions with different mechanisms as the cause of their symptoms).

Willing to defer initiation of discretionary treatments or supplements during the expected course of study participation.

Exclusion

Participating in another clinical trial.

Still-evolving adverse effects following another medication or health condition, such as covid or fluoroquinolone use.

On Coumadin/ warfarin.

Unable to participate for the required duration of the study.

What this trial measures

Number of symptoms (out of 20 on the UCSD Symptom Score Survey) showing more favorable change (trend or effect) on active treatment vs. on placebo.3.5 months
All outcomes are assessed as change from baseline.

Trialytics